Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000348165

Medchemexpress LLC Revumenib | 2169919-21-3 | 99.99% | 630.82 | 50 MG
SDP

Catalog No. 5000348165
Encompass_Preferred

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell-based IC50 of 10-20 nM. It can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

  • Potent and specific Menin-MLL inhibitor
  • Applicable for research into MLL-rearranged acute leukemias (ALL and AML)
  • Shows in vivo plasma IC50 of 53 nM
  • Provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts in vivo

Catalog No. 50-003-48165 Supplier Medchemexpress LLC Supplier No. HY13617550MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding Ki of 0.149 nM and a cell-based IC50 of 10-20 nM. It can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

  • Potent and specific Menin-MLL inhibitor
  • Applicable for research into MLL-rearranged acute leukemias (ALL and AML)
  • Shows in vivo plasma IC50 of 53 nM
  • Provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts in vivo

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.